New vaccine that could help defeat MenB
29 March 2017
Meningitis Research Foundation (MRF) welcomes the news that a new meningitis vaccine - Trumenba® - has been given positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to prevent meningococcal B meningitis and septicaemia (MenB).
Trumenba (manufactured by Pfizer) is only the second vaccine designed to provide broad protection against circulating MenB strains to be approved in Europe (following Bexsero® manufactured by GSK and licensed in 2013). Trumenba has been approved for use in individuals 10 years and older, while Bexsero can be administered from two months of age. The UK was the first country to introduce an immunisation programme using Bexsero and it is now routinely given to babies under the age of one. Both Trumenba and Bexsero are already licensed and available in the US.
Responding to this news, Vinny Smith, Chief Executive of MRF said, “We are delighted to see Trumenba recommended for license in Europe for individuals 10 years of age and older. Meningococcal B infection has for decades been the largest cause of life-threatening meningitis in the UK. Introducing the Bexsero vaccine for babies in 2015 was a major step forward. Having Trumenba recommended by the CHMP is another positive step forward. It is important to have multiple tools at our disposal to combat this disease and time will tell how each vaccine can play its part in helping us to defeat MenB.”
Hi, I’m Sam and I’m MRF's PR Manager.
If you want to know more about this story call me on 0333 405 626251, out of office hours on 07875 498047 or email firstname.lastname@example.org